potassium chloride 10 MEQ Extended Release Oral Tablet
potassium chloride
RxCUI: 628953
What the CMS Formulary Data Shows for potassium chloride 10 MEQ Extended Release Oral Tablet
Per the CMS 2026 Part D formulary file, potassium chloride 10 MEQ Extended Release Oral Tablet (RxNorm concept RXCUI 628953, generic name potassium chloride) appears on 330 distinct formulary files spanning 5,067 Medicare Part D plan offerings - 100% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 1.6.
Real-world access to potassium chloride 10 MEQ Extended Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,479,756 Part D beneficiaries filled potassium chloride 10 MEQ Extended Release Oral Tablet in 2023, with total plan-and-beneficiary spending of $396,202,925 and an average per-beneficiary annual cost of $113.86. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry potassium chloride 10 MEQ Extended Release Oral Tablet today.
Coverage Details
- Formularies covering
- 330
- Plans covering
- 5,067
- Coverage rate
- 100%
- Tier range
- Tier 1 – Tier 3
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,479,756
- Total spending
- $396,202,925
- Avg per beneficiary
- $113.86
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering potassium chloride 10 MEQ Extended Release Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is potassium chloride 10 MEQ Extended Release Oral Tablet covered by Medicare Part D?
Yes, potassium chloride 10 MEQ Extended Release Oral Tablet is covered by 5,067 Medicare Part D plans (100% of all Part D formularies).
What tier is potassium chloride 10 MEQ Extended Release Oral Tablet on Medicare Part D plans?
potassium chloride 10 MEQ Extended Release Oral Tablet averages Tier 1.6 across Part D plans, ranging from Tier 1 to Tier 3.
Does potassium chloride 10 MEQ Extended Release Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for potassium chloride 10 MEQ Extended Release Oral Tablet. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on potassium chloride 10 MEQ Extended Release Oral Tablet?
In 2023, total Medicare Part D spending on potassium chloride 10 MEQ Extended Release Oral Tablet was $396,202,925, covering 3,479,756 beneficiaries. The average spend per beneficiary was $113.86.
Read our methodology - how this data is sourced, computed, and verified.